Phase i study to determine MTD of docetaxel and cisplatin with concurrent radiation therapy for stage III non-small cell lung cancer

Chinese Journal of Cancer Research

Volumn 23, Issue 2, 2011, Pages 129-133

  Li, You Quan ^a   Shi, An Hui ^a   Li, Fu Hai ^a   Yu, Rong ^a   Zhu, Guang Ying ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

Cisplatin docetaxel; Concurrent chemoradiotherapy; Non small cell lung cancer; Toxicity

Indexed keywords

ANTIBIOTIC AGENT; ANTIEMETIC AGENT; CISPLATIN; DEXAMETHASONE; DIPHENHYDRAMINE; DOCETAXEL; RANITIDINE; VITAMIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CHEMORADIOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CONTROLLED STUDY; COUGHING; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG HYPERSENSITIVITY; DYSPNEA; ESOPHAGITIS; FATIGUE; FEMALE; FEVER; HISTOPATHOLOGY; HUMAN; INOPERABLE CANCER; INTENSITY MODULATED RADIATION THERAPY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MALE; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OPEN STUDY; PHASE 1 CLINICAL TRIAL; RADIATION DOSE; RADIATION ESOPHAGITIS; RADIATION INDUCED EMESIS; RADIATION INJURY; RADIATION PNEUMONIA; RADIATION SICKNESS; RANDOMIZED CONTROLLED TRIAL;

EID: 80051660374     PISSN: 10009604     EISSN: 19930631     Source Type: Journal    
DOI: 10.1007/s11670-011-0129-9     Document Type: Article

References (22)

1. Li LD, Yao KQ, Zhang SW, et al. Statistical Analysis of Data from 12 Cancer Registries in China. Bull Chin Cancer 2002; 11: 497-507.
2. Dillman RO, Herndon J, Seagren SL et al. Improved survival in Stage III nonsmall cell lung cancer: Seven-year follow-up of Cancer and Leukemia Group B (CALGB) 8433 trial. J Natl Cancer Inst 1996; 88: 1210-5. (Pubitemid 26302034)
3. Sause WT, Scott C, Taylor S, et al. RTOG 8808 ECOG 4588, 5-year results of a Phase III trial in regionally advanced unresectable non-small cell lung cancer [Abstract]. Proc Am Soc Clin Oncol 1998; 17: 453a.
4. Le Chevalier T, Arriagada R, Tarayre M, et al. Significant effect of adjuvant chemotherapy on survival in locally advanced non-small cell lung carcinoma. J Natl Cancer Inst 1992; 84: 58-65.
5. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 1995; 311: 899-909.
6. Schaake-Koning C, van den Bogaert W, Dalesio O, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer. N Engl J Med 1992; 326: 524-30.
7. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999; 17: 2692-9. (Pubitemid 29415225)
8. Curran W, Scott C, Langer C, et al. Phase III comparison of sequential vs. concurrent chemo radiation for pts. With unresected stage III non-small cell lung cancer (NSCLC): report of Radiation Therapy Oncology Group (RTOG) 9410. Lung cancer 2000; 29: 93.
9. Komaki R, Seiferheld W, Curran W, et al. Sequential vs. concurrent chemotherapy and radiation therapy for inoperable non-small cell lung cancer (NSCLC): analysis of failures in a phase III study (RTOG 9410) [Abstract]. Int J Radiat Oncol Biol Phys 2000; 48: 113.
10. Curran WJ Jr, Scott C, Langer C, et al. Phase III comparison of sequential vs concurrent chemoradiation for PTS with unresected stage III non-small cell lung cancer (NSCLC): Initial report of Radiation Therapy Oncology Group (RTOG) 9410. Proc Am Soc Clin Oncol 2000; 19: A-1891 (484a).
11. Choy H, Rodriguez F, Koester S, et al. Synergistic effects of Taxol/Taxotere on radiation sensitivity of human cell lines. Int J Radiat Oncol Biol Phys 1993; 24(Suppl 1): 1059.
12. Manson KA, Hunter NR, Milas M, et al. Docetaxel enhances tumor radioresponse in vivo. Clin Cancer Res 1997; 3: 2431-8. (Pubitemid 28133165)
13. Okamoto H, Watanabe K, Segawa Y, et al. Phase II study of docetaxel and cisplatin in patients with previous untreated metastatic non-small-cell lung cancer. Int J Clin Oncol 2000; 5: 316-22.
14. Zhu GY, Shi AH, Yu R, et al. The short and long term results of paclitaxel dose escalating study during concurrent radiotherapy for Chinese patients with locally advanced non-small cell lung cancer. ASTRO 2006; 2510.
15. National Cancer Institute Common Toxicity Criteria. Version 2.0, June 1, 1999.
16. Choy H, Akerley W, Safran H, et al. Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small-cell lung cancer. J Clin Oncol 1994; 12: 2682-6. (Pubitemid 24379656)
17. Choy H, DeVore RF, Hande KR, et al. Phase I trial of outpatient weekly docetaxel (DTX) carboplatin (DBDCA) and concurrent thoracic radiation therapy (TRT) for stage III unresectable non-small-cell lung cancer: A Vanderbilt Cancer Center Affiliate Network (VCCAN) Trial. Lung Cancer 2001; 34: 441-9.
18. Hennequin C, Giocanti N, Favaudon V. Interaction of ionizing radiation with paclitaxel (Taxol) and docetaxel (Taxotere) in HeLa and SQ20B Cells. Cancer Res 1996; 56: 1842-50.
19. Mudad RM, Ramsev M, Kovin K, et al. Concomitant weekly docetaxel, cisplatin and radiation therapy in locally advanced non-small cell lung cancer: a dose finding study. Lung Cancer 2003; 39: 173-7.
20. Sakai H, Yoneda S, Kobayashi K, et al. Phase II study of bi-weekly docetaxel and carboplatin with concurrent thoracic radiation therapy followed by consolidation chemotherapy with docetaxel plus carboplatin for stage III unresectable non-small cell lung cancer. Lung Cancer 2004; 43: 195-201. (Pubitemid 38114748)
21. Brunsviq PF, Hatlevoll R, Berg R, et al. Weekly docetaxel with concurrent radiotherapy in locally advanced non-small cell lung cancer: A Phase I/II study with 5 years' follow-up. Lung Cancer 2005; 50: 97-105. (Pubitemid 41297476)
22. Wu HG, Bang YJ, Choi EK, et al. Phase I study of weekly docetaxel and cisplatin concurrent with thoarcic radiotherapy in stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2002; 52: 75-80. (Pubitemid 34044107)